Real-World study tracks eczema Drug's performance outside the lab

NCT ID NCT06353087

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 13 times

Summary

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how well the drug controls symptoms like itching and rash over 12 months in real-world settings. The goal is to see if the improvements seen in clinical trials hold up in everyday life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang Gung Hospital Linkou

    NOT_YET_RECRUITING

    Taoyuan District, 333, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung

    RECRUITING

    Kaohsiung City, 83301, Taiwan

  • Kaohsiung Medical University Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, 807377, Taiwan

  • MacKay Memorial Hospital

    NOT_YET_RECRUITING

    Taipei, 10449, Taiwan

  • NTUH

    RECRUITING

    Taipei, 100, Taiwan

  • Taipei Medical University - Shuang Ho Hospital

    NOT_YET_RECRUITING

    New Taipei City, 23561, Taiwan

  • Taipei Veterans General Hospital

    NOT_YET_RECRUITING

    Taipei, 11217, Taiwan

  • Tri-Service General Hospital

    NOT_YET_RECRUITING

    Taipei, 11490, R.O.C., Taiwan

Conditions

Explore the condition pages connected to this study.